in this issue
EnviroTech :: Biotech
Sanofi-Aventis Signs Licensing Agreement with U.S. Biotech Firm
4:14 AM MDT | October 2, 2009 | Deepti Ramesh
Sanofi-Aventis (Paris) says it has entered into an exclusive global collaboration and licensing agreement with biotechnology company Merrimack Pharmaceuticals (Cambridge, MA) for MM-121, a monoclonal antibody in oncology. MM-121 is currently in Phase 1 clinical testing. Sanofi-Aventis will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121, under the terms of the deal. Merrimack will retain potential co-promotion rights in the U.S. MM-121 is a pioneering monoclonal antibody which brings a new innovative approach to...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee